Literature DB >> 32793688

Effects of primary hypertension treatment in the oncological outcomes of hepatocellular carcinoma.

Victor Lopez-Lopez1, Alvaro Gomez Ruiz1, Asunción Lopez-Conesa1, Roberto Brusadin1, Valentin Cayuela1, Albert Caballero-Illanes2, Máximo Torres3, Ricardo Robles Campos1.   

Abstract

Entities:  

Year:  2020        PMID： 32793688      PMCID： PMC7396803          DOI： 10.21037/atm.2020.04.40

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  22 in total

1.  The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.

Authors:  H Yoshiji; S Kuriyama; M Kawata; J Yoshii; Y Ikenaka; R Noguchi; T Nakatani; H Tsujinoue; H Fukui
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

2.  Doxycycline as an inhibitor of the epithelial-to-mesenchymal transition and vasculogenic mimicry in hepatocellular carcinoma.

Authors:  Jie Meng; Baocun Sun; Xiulan Zhao; Danfang Zhang; Xueming Zhao; Qiang Gu; Xueyi Dong; Nan Zhao; Peimei Liu; Yanrong Liu
Journal:  Mol Cancer Ther       Date:  2014-10-02       Impact factor: 6.261

3.  Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome.

Authors:  Allison J Kasmari; Amy Welch; Guodong Liu; Doug Leslie; Thomas McGarrity; Thomas Riley
Journal:  Am J Med       Date:  2017-01-19       Impact factor: 4.965

Review 4.  The changing role of beta-blocker therapy in patients with cirrhosis.

Authors:  Phillip S Ge; Bruce A Runyon
Journal:  J Hepatol       Date:  2013-09-26       Impact factor: 25.083

Review 5.  The renin-angiotensin system and malignancy.

Authors:  Eleanor I Ager; Jaclyn Neo; Christopher Christophi
Journal:  Carcinogenesis       Date:  2008-07-16       Impact factor: 4.944

6.  Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma.

Authors:  Matthias Pinter; Arndt Weinmann; Marcus-Alexander Wörns; Florian Hucke; Simona Bota; Jens U Marquardt; Dan G Duda; Rakesh K Jain; Peter R Galle; Michael Trauner; Markus Peck-Radosavljevic; Wolfgang Sieghart
Journal:  United European Gastroenterol J       Date:  2017-02-26       Impact factor: 4.623

7.  Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.

Authors:  Krishnan Bhaskaran; Ian Douglas; Stephen Evans; Tjeerd van Staa; Liam Smeeth
Journal:  BMJ       Date:  2012-04-24

8.  Renin-angiotensin inhibitors were associated with improving outcomes of hepatocellular carcinoma with primary hypertension after hepatectomy.

Authors:  Long-Hai Feng; Hui-Chuan Sun; Xiao-Dong Zhu; Shi-Zhe Zhang; Kang-Shuai Li; Xiao-Long Li; Yan Li; Zhao-You Tang
Journal:  Ann Transl Med       Date:  2019-12

9.  Meta-analysis of studies using statins as a reducer for primary liver cancer risk.

Authors:  Guo-Chao Zhong; Yan Liu; Yuan-Yuan Ye; Fa-Bao Hao; Kang Wang; Jian-Ping Gong
Journal:  Sci Rep       Date:  2016-05-20       Impact factor: 4.379

10.  Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study.

Authors:  Cheng-Maw Ho; Chih-Hsin Lee; Ming-Chia Lee; Jun-Fu Zhang; Jann-Yuan Wang; Rey-Heng Hu; Po-Huang Lee
Journal:  BMC Cancer       Date:  2018-04-10       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.